Author: Xiaoli Zhao

We’ve issued a new notice: NIGMS Support to Utilize Data and Biospecimens Generated by the ARDS, Pneumonia, and Sepsis (APS) Phenotyping Consortium (NOT-GM-24-018). The purpose is to inform investigators that we’ll support studies that fall within the NIGMS mission and utilize biospecimens or data generated from the APS Consortium.

We want the research community to know about two funding opportunity announcements (FOAs) that NIGMS has joined as part of an NHLBI initiative to support the formation of a multisite study, the Acute Respiratory Distress Syndrome (ARDS), Pneumonia, and Sepsis Phenotyping (APS) Consortium. The study seeks to better define the heterogeneity underlying critical illness syndromes and to identify the mechanisms of illness development and recovery, as well as relationships and overlap between these syndromes. The FOAs are:

We’ve issued a new funding opportunity announcement (FOA): Exploring the Scientific Value of Existing or New Sepsis Human Biospecimen Collections (R21/R33 – Clinical Trial Not Allowed) (PAR-21-077). This FOA aims to promote the optimal use, testing, and sharing of patient-derived materials. It stems from recommendations of the NAGMSC working group on sepsis and input from the scientific community for strategies to rebalance NIGMS’ investment in sepsis research.